WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene
Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration. The multi-year collaboration will focus on the identification and development of small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit, against targets for a range of oncology, neurodegenerative and inflammatory indications.
The WilmerHale deal team counseling Vividion included Steven Singer, Steven Barrett and Mat Trachok.
Read Vividion Therapeutics' press release for more information.